29685-73-2

Basic information

• Product Name: (E)-4-(4-(tert-butyl)phenyl)-4-oxobut-2-enoic acid
• Synonyms: (E)-4-(4-(tert-butyl)phenyl)-4-oxobut-2-enoic acid
• CAS NO: 29685-73-2
• Molecular Weight: 232.279
• Mol File: 29685-73-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (E)-4-(4-(tert-butyl)phenyl)-4-oxobut-2-enoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-4-(4-(tert-butyl)phenyl)-4-oxobut-2-enoic acid(29685-73-2)
• EPA Substance Registry System: (E)-4-(4-(tert-butyl)phenyl)-4-oxobut-2-enoic acid(29685-73-2)

Safety Data

• Hazardous Substances Data: 29685-73-2(Hazardous Substances Data)

Upstream product

• 939-97-9 4-tert-Butylbenzaldehyde 
• 1073375-56-0 ethyl 4-(4-(tert-butyl)phenyl)-4-oxobut-2-enoate 
• 108-31-6 maleic anhydride 
• 1012-72-2 1,4-di-tert-butylbenzene 
• 253185-03-4 tert-butylbenzene 

Downstream Products

• 1073375-56-0 ethyl 4-(4-(tert-butyl)phenyl)-4-oxobut-2-enoate 

Relevant articles and documents

Design and synthesis of novel antimicrobials with activity against Gram-positive bacteria and mycobacterial species, including M. tuberculosis

The alarming increase in bacterial resistance over the last decade along with a dramatic decrease in new treatments for infections has led to problems in the healthcare industry. Tuberculosis (TB) is caused mainly by Mycobacterium tuberculosis which is responsible for 1.4 million deaths per year. A world-wide threat with HIV co-infected with multi and extensively drug-resistant strains of TB has emerged. In this regard, herein, novel acrylic acid ethyl ester derivatives were synthesized in simple, efficient routes and evaluated as potential agents against several Mycobacterium species. These were synthesized via a stereospecific process for structure activity relationship (SAR) studies. Minimum inhibitory concentration (MIC) assays indicated that esters 12, 13, and 20 exhibited greater in vitro activity against Mycobacterium smegmatis than rifampin, one of the current, first-line anti-mycobacterial chemotherapeutic agents. Based on these studies the acrylic ester 20 has been developed as a potential lead compound which was found to have an MIC value of 0.4 μg/mL against Mycobacterium tuberculosis. The SAR and biological activity of this series is presented; a Michael-acceptor mechanism appears to be important for potent activity of this series of analogs.

Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof

The present invention relates to compounds of general formula [in-line-formulae]R—Z1—Z2—Z3—R1, ??(I)[/in-line-formulae] wherein R, R1 and Z1 to Z3 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these compounds, their use and processes for preparing them.